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Men-Bao Qian1*, Ying-Dan Chen1 and Fei Yan2Abstract
Recent publication of the global epidemiology of clonorchiasis and its relationship with cholangiocarcinoma in the
journal of Infectious Diseases of Poverty has stressed the importance of Clonorchis sinensis infection. To further
demonstrate its threat on public health, especially in China, comparisons between clonorchiasis and hepatitis B are
made in terms of epidemiology, clinical symptoms and carcinogenicity, disability, as well as changing trends.
Furthermore, major problems and prioritized researches are argued, from basic biology to intervention. Imbalance
between the majority of infected population and the minority of researches in China urges for more work from
Chinese scientists and international cooperation.
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Please see Additional file 1 for translations of the ab-
stract into the six official working languages of the
United Nations.
Background
A review on the global epidemiology of clonorchiasis
and its relationship with cholangiocarcinoma (CCA) was
published in the journal of Infectious Diseases of Poverty
on 25th October 2012 [1]. A total of 15 million people
are estimated to be infected with Clonorchis sinensis in
East Asia and nearly 5,000 CCA cases attributed to this
infection may occur annually in the coming decades.
That article seeks to elucidate the situation and impact
of clonorchiasis. However, some more deserve to be
discussed, especially in China.
Discussion
Comparisons between clonorchiasis and hepatitis B
in China
Clonorchiasis ranks among the top neglected tropical
diseases [2]. Thus, comparing it with hepatitis B will
promote revealing its threat on public health in China.
Firstly, most people infected with hepatitis B virus
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reproduction in any medium, provided the orinfections. A total population of 93 million is infected
with HBV in China, which is about one quarter of the
global number [3,4], while out of 15 million with C.
sinensis infection globally, over 85% distributes in China
(Figure 1A) [1]. Even after including another liver fluke in-
fection, opisthorchiasis, the number in China is still over
50% (Figure 2B) [1,5,6]. Similar distribution characteristics
in sexes and ages are shown in both infections, namely
higher prevalence in males than in females and in adults
than in children [1,7].
Secondly, as HBV mainly attacks the liver, C. sinensis
infection also causes liver diseases, as well as biliary
conditions. Although there are differences, some similar-
ities may lead to misdiagnosis. Both may present non-
specific symptoms or signs, such as fatigue, loss of
appetite, fever, nausea, abdominal pain, jaundice and
hepatomegaly [8,9]. What is most similar is that both
can cause liver cancer [10,11]. Hepatocellular carcinoma
and CCA are the two most common types of liver can-
cer [12]. HBV is a definite carcinogen to hepatocellular
carcinoma, while C. sinensis is the one to CCA [10,11].
Meta-analyses captured a general odds ratio of 15.6 for
HBV infection in causing hepatocellular carcinoma [13],
and 4.5 for C. sinensis infection in causing CCA [1]. In-
flammation is the crucial factor in the carcinogenesis of
both agents [10]. As the carcinogenicity is associated
with the virus load in HBV [14], it is relevant to the in-
fection intensity in Opisthorchis viverrini-homologous to
C. sinensis [15].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Population with liver fluke infections globally. A: Population with clonorchiasis. B: Population with clonorchiasis and opisthorchiasis.
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nificant disability. An average disability weight of 0.075
in C. sinensis infection is captured through community
survey and model simulation [16], which is unexpectedly
the same as that in hepatitis B [17].
Nevertheless, different changing trends appear. Al-
though there is no availability of treatment to completely
clear HBV, efficient vaccine and great efforts contribute
to its obvious decline, especially in China [4,7,18]. Even
though specific drug, namely praziquantel, is available,
neglect and re-infection cause the significant increase in
clonorchiasis [1,2].
Although there are fundamental differences in biology
and some other aspects, comparisons above justify the
public health importance of C. sinensis infection in
China. Even though a relatively smaller population is
infected with C. sinensis as compared with HBV nation-
ally, the impact of clonorchiasis challenges hepatitis B in
major endemic areas, namely the east part of China
[1,19], where the former is becoming another killer of
the liver and biliary health. The great success in control-
ling hepatitis B in China should provide valuable lessons
for tackling clonorchiasis.Figure 2 Number of papers documented in Pubmed on liver flukes fr
listed in Additional file 2. A: Papers focusing on liver flukes. B: Papers focusMore problems raised and more researches needed in
China
Recently, the Disease Reference Group on Helminth
Infections (DRG4) established by the Special Programme
for Research and Training in Tropical Diseases ranked
prioritized researches for the control and elimination of
major human helminthiases, including clonorchiasis [20].
Indeed, some have also been pointed out directly or indir-
ectly in our former article.
Although three large-scale surveys involving clonorchiasis
in China promote understanding the national situation and
changes, epidemiology is only captured at the provincial
level rather than at the county or lower level, which
hampers the implementation of intervention measurements.
Therefore, new methods, such as spatial techniques and
modeling, deserve to be introduced to draw an epidemio-
logical map for the disease [21,22]. Even though some epi-
demiological characteristics are known, social ecology and
environmental determinants need to be elucidated further,
such as the inherent drive for raw-fish-eating behavior, the
cycle of infection-treatment-re-infection, factors involving in
distributing and taking drug, roles of intermediate hosts, cli-
mate change [23], the property of zoonosis [24] and so on.om China, the Republic of Korea and Thailand. Searching strategy
ing on liver flukes and cholangiocarcinoma.
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co-endemic in China challenges more accurate diagno-
sis, especially molecular methods [1,25]. Although two
endemic zones have been classified [1] and some
differences in biology have also been found [26], whether
there exist differences in morbidity, especially in CCA, are
also expected to be explored. It is already known that
infection intensity is associated with carcinogenesis in
O. viverrini infection [15], but corresponding studies
in C. sinensis infection are not yet available, which
causes unreasonably adopting the same OR in calcu-
lating CCA incidence in both sexes [1]. Furthermore,
the impact of co-endemicity of C. sinensis and HBV
infections on morbidity, especially on liver cancer in the
east part of China, needs to be evaluated. Obviously, the
establishment of tumor registry in China will promote
related researches. Massive drug administration still counts
on single drug, praziquantel [27], but no standardized
principles of management are yet available. Additionally,
tribendimidine, which shows promising efficiency against
C. sinensis infection in vivo, in vitro, and in small field test,
is expected to be further evaluated [28-30].
Even though most of the population infected with liver
flukes distribute in China, corresponding researches are
significantly less as compared with that in the Republic
of Korea and Thailand, especially in CCA (Figure 2A
and 2B, Additional file 2). The effort for controlling
clonorchiasis in China will determine the global agenda
for control and even elimination. Thus, more researches
are anticipated from Chinese scientific workers. As it
should be, international cooperation will be welcomed
for tackling this problem [31].
Summary
The comparability between clonorchiasis and hepatitis B
in epidemiology, clinical symptoms and carcinogenicity
and disability, and contrast in changing trends, justify
the threat of clonorchiasis and the urgency for interven-
tion in China. Prioritized researches covering topics
from basic biology to intervention are expected, which
will benefit the control and even final elimination of
clonorchiasis. However, the imbalance between the ma-
jority of infected population and the minority of
researches in China draws more challenges. Thus, more
efforts and outputs are expected from Chinese scientists,
as well as international cooperation.
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